Symptom Palliation in Patients with Bone Metastases Treated with Radiotherapy

Abstract

Context: Skeleton is the most common organ affected by metastases. Bone pain is the most common symptom of metastatic bone disease. The treatment of bone metastasis is primarily palliative requiring multidisciplinary therapies; radiotherapy (RT), however, remains the cornerstone of the treatment. Aims: The aim of this study is to measure the effectiveness of RT in terms of symptomatic relief in pain and insomnia, improvement in stability/movement, and decrease in the requirement of analgesics by patients using the Hundred Paisa Pain Scale. Subjects and Methods: The RT records of 226 patients with bone metastasis treated at the department of Radiotherapy, SMS Medical College, Jaipur; from July 2015 to December 2016 over cobalt-60 teletherapy unit were analyzed. The RT dose fractionation ranged from 30 Gy in 10 daily fractions, 20 Gy in 5 daily fractions, 12.5 Gy in 2 weekly fractions, and 8 Gy in single fraction. Results: The median age of the cohort was 54 (range, 29–84) years. The most common site of primary tumor was lung (30.1%), followed by breast (12.4%) and prostate (11.9%). The most common bone involved was vertebrae (71.2%), followed by pelvis (14.6%); among vertebrae, thoracic vertebrae were most commonly involved (63.9%), followed by lumbar vertebrae (57.8%). The maximum relief in pain was seen with 6.25 Gy/fraction schedule, whereas the maximum improvement in stability/movement was noted with 3 Gy/fraction schedule. The 8 Gy single-fraction schedule was associated with maximum relief in insomnia and decrease in analgesic requirement. Conclusion: The current institutional protocol of weekly hypofractionated palliative RT of 6.25 Gy per fraction up to a maximum of four fractions given on Saturday has shown results comparable with other schedules with well tolerance and achievement of acceptable symptom palliation. This weekly schedule is practically convenient to both the patients who mostly came from far-flung areas and the institute as it spares the already overburdened machine to carry on conventional RT from Monday to Friday.

Keywords

Bone metastases - palliation - radiotherapy

Publikationsverlauf

Artikel online veröffentlicht:
03. Juni 2021

• References

• 1 Coleman RE. Skeletal complications of malignancy. Cancer 1997; 80: 1588-94
• 2 Mercadante S. Malignant bone pain: Pathophysiology and treatment. Pain 1997; 69: 1-18
• 3 Fulfaro F, Casuccio A, Ticozzi C, Ripamonti C. The role of bisphosphonates in the treatment of painful metastatic bone disease: A review of phase III trials. Pain 1998; 78: 157-69
• 4 Galasko CS. Diagnosis of skeletal metastases and assessment of response to treatment. Clin Orthop Relat Res 1995; 312: 64-75
• 5 Slavik E, Ivanović S, Grujicić D. Cancer pain (classification and pain syndromes). Acta Chir Iugosl 2004; 51: 9-14
• 6 Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006; 12: 6243s-9s
• 7 Nielsen OS, Munro AJ, Tannock IF. Bone metastases: Pathophysiology and management policy. J Clin Oncol 1991; 9: 509-24
• 8 Mercadante S, Fulfaro F. Management of painful bone metastases. Curr Opin Oncol 2007; 19: 308-14
• 9 Lussier D, Huskey AG, Portenoy RK. Adjuvant analgesics in cancer pain management. Oncologist 2004; 9: 571-91
• 10 Cherny N. New strategies in opioid therapy for cancer pain. J Oncol Manag 2000; 9: 8-15
• 11 Mercadante S, Villari P, Ferrera P, Casuccio A. Optimization of opioid therapy for preventing incident pain associated with bone metastases. J Pain Symptom Manage 2004; 28: 505-10
• 12 Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 2008; 98: 1736-40
• 13 Hiraga T, Tanaka S, Yamamoto M, Nakajima T, Ozawa H. Inhibitory effects of bisphosphonate (YM175) on bone resorption induced by a metastatic bone tumor. Bone 1996; 18: 1-7
• 14 Major PP, Lipton A, Berenson J, Hortobagyi G. Oral bisphosphonates: A review of clinical use in patients with bone metastases. Cancer 2000; 88: 6-14
• 15 Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W. et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases. Cancer 2001; 91: 1191-200
• 16 Canadian Agency for Drugs and Technologies in Health. Denosumab (Xgeva). CADTH Common Drug Reviews. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2016
• 17 Dy SM, Asch SM, Naeim A, Sanati H, Walling A, Lorenz KA. et al. Evidence-based standards for cancer pain management. J Clin Oncol 2008; 26: 3879-85
• 18 Alghadir A, Anwer S, Anwar D, Nezamuddin M. The development and validation of hundred paisa pain scale for measuring musculoskeletal pain: A prospective observational study. Medicine (Baltimore) 2015; 94: e1162
• 19 van den Beuken-van Everdingen MH, de Rijke JM, Kessels AG, Schouten HC, van Kleef M, Patijn J. Prevalence of pain in patients with cancer: A systematic review of the past 40 years. Ann Oncol 2007; 18: 1437-49
• 20 Ziu E, Mesfin FB. Cancer, Metastasis, Spinal. Source StatPearls. Treasure Island (FL): StatPearls Publishing; 2017
• 21 Kapoor A, Singhal MK, Kumar N, Kalwar A, Bagri PK, Narayan S. et al. Analysis of patterns of palliative radiotherapy in North West India: A regional cancer center experience. Indian J Palliat Care 2015; 21: 168-73
• 22 Li KK, Chow E, Chiu H, Bradley N, Doyle M, Barnes EA. et al. Effectiveness of palliative radiotherapy in the treatment of bone metastases employing the brief pain inventory. J Cancer Pain Symptom Palliation 2006; 2: 19-29
• 23 Kapoor A, Singhal MK, Bagri PK, Nirban RK, Maharia S, Narayan S. et al. Comparison of single versus multiple fractions for palliative treatment of painful bone metastasis:First study from North West India. Indian J Palliat Care 2015; 21: 45-8
• 24 Kumar SP. Utilization of brief pain inventory as an assessment tool for pain in patients with cancer: A focused review. Indian J Palliat Care 2011; 17: 108-15
• 25 Price DD, Staud R, Robinson ME. How should we use the visual analogue scale (VAS) in rehabilitation outcomes? II: Visual analogue scales as ratio scales: An alternative to the view of Kersten et al.. J Rehabil Med 2012; 44: 800-1
• 26 Chakraborty A, Mathur S. Rupee scale: For measurement of pain in India. Internet J Anesthesiol 2006; 12: 2
• 27 Janjan NA. Radiation for bone metastases: Conventional techniques and the role of systemic radiopharmaceuticals. Cancer 1997; 80: 1628-45
• 28 Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P. et al. Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79: 965-76
• 29 Falkmer U, Järhult J, Wersäll P, Cavallin-Ståhl E. A systematic overview of radiation therapy effects in skeletal metastases. Acta Oncol 2003; 42: 620-33
• 30 Berg RS, Yilmaz MK, Høyer M, Keldsen N, Nielsen OS, Ewertz M. Half body irradiation of patients with multiple bone metastases: A phase II trial. Acta Oncol 2009; 48: 556-61
• 31 Spartacus RK, Dana R, Rastogi K, Bhatnagar AR, Daga D, Gupta K. Hypofractionated radiotherapy for palliation in locally advanced head and neck cancer. Indian J Palliat Care 2017; 23: 313-6